GSK is not responsible for content on third-party websites. LAIV4 should not be used during pregnancy. In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here. FLULAVAL QUADRIVALENT has been administered in 8 clinical trials to 1,384 adults aged 18 years and older, 1,965 children aged 6 through 35 months, and 3,516 children aged 3 through 17 years. Persons ≥36 months (≥3 years) should receive 0.5mL per dose. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope, If FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons, In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. Infants and younger children: the anterolateral thigh is the preferred site. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. If a vaccine other than ccIIV4 or RIV4 is selected for such a person, it should be administered in an inpatient or outpatient medical setting and supervised by a health care provider who is able to recognize and manage severe allergic reactions. :z“Õ~�sè¿Oé„Ô§ ø´Zù Health care personnel or hospital visitors who receive LAIV4 should avoid providing care for severely immunosuppressed persons requiring a protected environment for 7 days after vaccination. FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Compare Fluarix vs Fluzone head-to-head with other drugs for uses, ratings, cost, side … The same dose (0.5-mL) for all your recommended patients (aged 6 months and older).1,2, Rely on one prefilled syringe (PFS) of FLUARIX QUADRIVALENT to cover all recommended ages.1,2. VAERS serves as an early warning system to detect possible safety problems with U.S. vaccines. Archive, Vaccinate Adults
LAIV4 is not recommended for persons with some chronic medical conditions (see. Javascript is not enabled in your browser, so
Archive, Vaccinate Women
Detailed guidance for administration sites and needle length is available in the Best Practice Guidelines of the Advisory Committee on Immunization Practices (ACIP) at. If a 0.25mL intramuscular dose is administered to a person ≥36 months of age: If the error is discovered immediately, administer the remaining additional volume needed to provide a full dose. ©2020 GSK or licensor.
Please update your operating system or use a different device.
Please see full Prescribing Information for FLUARIX QUADRIVALENT. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older. Consult package information for age indications.
You will be subject to the destination website's privacy policy when you follow the link. You now have access to the latest updates, events and resources. ADULT &, Needle Tips
Influenza Vaccine Products for the 2020–2021 Influenza Season
You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. For children needing two doses, the second dose is recommended even if the child turns age 9 years between dose 1 and dose 2.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Please update your operating system or use a different device.
GSK Medical Information: 1-877-GSK-MI4U (1-877-475-6448). In all cases, manufacturer packaging information should be consulted for authoritative guidance regarding storage and handling of influenza vaccines. In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number. some features on this page may not work correctly. Timing vaccination during some period either before or after interventions which compromise immunity may be appropriate. The site is secure.
July 2, 2019 - Approval Letter - Fluarix Quadrivalent June 29, 2018 Approval Letter - Fluarix Quadrivalent To include the 2018-2019 United State formulation and associated labeling revisions. Moderate or severe acute illness with or without fever. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Templates, Temperature
Event registration completed - pending validation.
In the meantime, you can enjoy the public content on our website.
Half of the total sprayer contents is sprayed into the first nostril while the recipient is in the upright position. Emphasis should be placed on vaccination of high-risk groups and their contacts/caregivers.
Vaccination with Southern Hemisphere influenza vaccine prior to travel to the Southern Hemisphere may be reasonable; however, only one Southern Hemisphere formulation is licensed by FDA (Fluzone Quadrivalent Southern Hemisphere, Sanofi Pasteur),and it is generally not commercially available in the U.S. IIV and RIV4 may be administered to persons receiving influenza antiviral medications for treatment or chemoprophylaxis. Checklists, Standing Orders
Package information may also specify a maximum number of doses contained in multidose vials (regardless of remaining volume). Abbreviations: IIV=inactivated influenza vaccine; RIV=recombinant influenza vaccine; HA=hemagglutinin; mos=months; yrs=years. Content Path:/content/cf-pharma/health-hcpportal/en_US/hcp/home.
If the vaccine recipient sneezes immediately after administration, the dose should not be repeated. RIV4 is licensed for persons aged ≥18 years and should not be used for children aged <18 years.